个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Zhou, Q.[1] * ; Zhang, H.[2] ; Jiang, L.[3] ; Shi, Y.[4,5] ; Chen, Y.[6] ; Yu, J.[7] ; Zhou, C.[8] ; He, Y. ; Hu, Y.[9] ; Liang, Z-A.[10] ; Pan, Y.[11] ; Zhuo, W.[12] ; Song, Y.[13,14] ; Wu, G.[15] ; Chen, G.[16] ; Lu, Y.[17] ; Cheng, Y.[18] ; Lu, S.[19] ; Wang, J.[4,5] ; Wu, Y. L.[20] ;
单位： [1]Guangdong Gen Hosp, Med Oncol, Guangzhou, Guangdong, Peoples R China [2]Air Force Mil Med Univ, Tangdu Hosp, Oncol, Xian, Shaanxi, Peoples R China [3]Shanghai Chest Hosp, Pulm Med, Shanghai, Peoples R China [4]Chinese Acad Med Sci, Canc Hosp, Natl Canc Center, Med Oncol, Beijing, Peoples R China [5]Peking Union Med Coll, Beijing, Peoples R China [6]Tongji Hosp, Oncol, Wuhan, Hubei, Peoples R China [7]Shandong Canc Hosp, Radiotherapy, Jinan, Shandong, Peoples R China [8]Shanghai Pulm Hosp, Oncol, Shanghai, Peoples R China [9]Hubei Canc Hosp, Oncol Med, Wuhan, Hubei, Peoples R China [10]Sichuan Univ, West China Hosp, Resp, Chengdu, Sichuan, Peoples R China [11]Anhui Prov Hosp, Oncol Med, Hefei, Anhui, Peoples R China [12]Mil Med Univ, Xinqiao Hosp, Oncol, Chongqing, Peoples R China [13]Nanjing Gen Hosp Nanjing Mil Command, Oncol, Nanjing, Jiangsu, Peoples R China [14]PLA Bayi Hosp, Nanjing, Jiangsu, Peoples R China [15]Huazhong Univ Sci & Technol, Union Hosp, Canc Ctr, Wuhan, Hubei, Peoples R China [16]Harbin Med Univ, Tumor Hosp, Resp Oncol, Harbin, Heilongjiang, Peoples R China [17]Sichuan Univ, West China Hosp, Oncol, Chengdu, Sichuan, Peoples R China [18]Jilin Canc Hosp, Jilin Canc Inst, Jilin Lung Canc Diag & Treatment Ctr, Med Oncol, Jilin, Jilin, Peoples R China [19]Shanghai Chest Hosp, Oncol Med, Shanghai, Peoples R China [20]Guangdong Gen Hosp, Canc Ctr, Guangzhou, Guangdong, Peoples R China
出处：
ISSN：
基金：
AstraZeneca
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2016]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者：
第一作者单位： [1]Guangdong Gen Hosp, Med Oncol, Guangzhou, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Zhou Q.,Zhang H.,Jiang L.,et al.Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study[J].ANNALS OF ONCOLOGY.2018,29:158-158.
APA：
Zhou, Q.,Zhang, H.,Jiang, L.,Shi, Y.,Chen, Y....&Wu, Y. L..(2018).Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study.ANNALS OF ONCOLOGY,29,
MLA：
Zhou, Q.,et al."Osimertinib in advanced or metastatic non-small cell lung cancer patients with EGFR T790M mutation after treatment with EGFR-TKI: Interim analysis of China cohort from the single-arm, open-label, international, multi-center real-world ASTRIS study".ANNALS OF ONCOLOGY 29.(2018):158-158

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）